Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia
- PMID: 20965784
- DOI: 10.1016/S1470-2045(10)70243-6
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia
Comment on
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19. Lancet Oncol. 2010. PMID: 20965785 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous